Patents Examined by My-Chau T Tran
  • Patent number: 11141408
    Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: October 12, 2021
    Assignee: VELOXIS PHARMACEUTICALS INC.
    Inventor: William J. Polvino
  • Patent number: 11123335
    Abstract: The present invention relates to a method for inhibiting lung diseases in smokers and non-smokers by blocking growth factor signaling using an antihypertensive drug, and more particularly, to a pharmaceutical composition for preventing lung cancer or emphysema, which contains an antihypertensive drug as an active ingredient. The present invention suggests a novel use of an antihypertensive drug which is being used in clinics, to prevent lung diseases, and therefore, may be readily applied to early lung cancer or a lung cancer high-risk group, and particularly may exclude safety concerns accompanying clinical application of novel drugs, thereby increasing clinical applicability. In addition, enormous costs and time needed from development to clinical use of new drugs may be dramatically reduced.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 21, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Ho-Young Lee, Hye-Young Min, Hye-Jin Boo, Hyun-Ji Jang
  • Patent number: 11123320
    Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 21, 2021
    Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
  • Patent number: 11116762
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: September 14, 2021
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Patent number: 11116735
    Abstract: A use of a substituted benzoguanidine derivative as a polymyxin antibiotic synergist, particularly as a synergist and a drug resistance reversal agent of the polymyxin antibiotic for inhibiting a sensitive strain, or a composition comprising the same in combination with a polymyxin antibiotic for preparing a compound pharmaceutical preparation for human or animal use in the treatment of a disease caused by a gram-negative bacterial infection or the preparation a growth-promoting feed additive and for the raising of livestock animals.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: September 14, 2021
    Assignee: GUANGZHOU INSIGHTER BIOTECHNOLOGY CO., LTD.
    Inventors: Xianfeng Peng, Zonghua Qin
  • Patent number: 11110098
    Abstract: The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the present disclosure provides methods, uses, and medicaments that include such select V2R antagonists for utility in treating clear cell renal cell carcinoma.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 7, 2021
    Assignee: University of Kansas
    Inventor: Reena Rao
  • Patent number: 11104955
    Abstract: The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: August 31, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arin K. Greene, Matthew Warman, Yue Huang
  • Patent number: 11103476
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 31, 2021
    Assignee: NIPPON SUISAN KAISHA, LTD.
    Inventors: Jiro Takeo, Hiroyuki Kawahara
  • Patent number: 11098368
    Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 24, 2021
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
  • Patent number: 11091468
    Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: August 17, 2021
    Assignees: Research Foundation of the City University of New York, Texas Tech University System
    Inventors: Adam B. Braunschweig, Kalanidhi Palanichamy, M. Fernando Bravo, Milan A. Shlain, Himanshu Garg, Anjali Joshi
  • Patent number: 11090311
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 17, 2021
    Assignee: Board of Regents, the University of Texas System
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 11083737
    Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 10, 2021
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
  • Patent number: 11077102
    Abstract: A multidose package containing an imiquimod formulation suitable for treating topical conditions includes: a) a dispensing aperture for dispensing the formulation from the package; b) a reservoir containing sufficient formulation to provide two or more doses; c) a metered dosage element for measuring a predetermined dose of the formulation, the element including an inlet from the reservoir and an outlet to the dispensing aperture; and d) an actuating element operating the dosage element so the predetermined dose is delivered to the dispensing aperture; wherein the dose is dispensed without microbial or other contamination or degradation of the formulation in reservoir. A corresponding course of treatment for various maladies includes providing a multidose package containing an imiquimod formulation suitable for the treatment. A corresponding method of treatment of diseases with multiple doses of an imiquimod formulation includes multiple doses provided by a multidose package.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 3, 2021
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Mark J. Hutchings, Christiaan M. Niekerk
  • Patent number: 11077121
    Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 3, 2021
    Assignees: Institute For Cancer Research, Institut Curie, Institut de Genetique et de Biologie Moleculaire et Cellulaire
    Inventors: Alfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
  • Patent number: 11065266
    Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 20, 2021
    Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Mildred Enid Acevedo-Duncan, Wishrawana Sarathi Ratnayake, David A. Ostrov
  • Patent number: 11058665
    Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: July 13, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Joan Massague, Adrienne Boire, Qing Chen
  • Patent number: 11040042
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: June 22, 2021
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Patent number: 11040016
    Abstract: The present invention relates to a use of D-chiro-inositol, pinitol, or analog compounds thereof for preventing or treating female menopausal symptoms. The active ingredient compound of the present invention has an effect of increasing the activity of female hormones by increasing the blood concentration of 17?-estradiol and lowering the blood concentration of sex hormone-binding globulin. Therefore, the active ingredient compound of the present invention can be developed as a drug or a nutraceutical for preventing, alleviating or treating female menopausal symptoms. The active ingredient of the present invention is derived from a natural product, and thus, unlike an agonist of female sex hormones or chemically synthesized sex hormones, has very few side effects when applied to the human body.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 22, 2021
    Assignee: DY NATURAL CO., LTD
    Inventors: Hyeon Koon Myeong, Kwang Kyu Kim
  • Patent number: 11040037
    Abstract: The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 22, 2021
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 11033529
    Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 15, 2021
    Assignee: Cortice Biosciences, Inc.
    Inventors: Michael Weiser, Jason Stein, Donald Picker